PEGBIO CO-B (02565) surged more than 30% in early trading, reaching HK$5, with current turnover of approximately HK$80.5163 million.
On the news front, the company's core product, Vipenatide Injection (Paidakang®), has received approval from the National Medical Products Administration for market launch. As a once-weekly GLP-1 receptor agonist, the product features differentiated characteristics including immediate treatment initiation without the need for dose titration.
The company previously entered into an exclusive commercialization partnership with Tengrui Pharmaceutical for the Chinese mainland market, continuously advancing the product's commercialization layout across medical institutions and online channels.
Notably, Vipenatide has entered the relevant procedures for the 2026 national medical insurance catalog adjustment. As the announcement of the new round of the national medical insurance catalog approaches, the product's medical insurance access progress has attracted market attention. If successfully included in the medical insurance list, it is expected to further enhance patient medication accessibility and create conditions for subsequent commercialization volume growth.
Additionally, the company continues to advance research and development of next-generation innovative drugs for metabolic diseases. Among them, the circular RNA project CR059 is dedicated to achieving long-acting GLP-1 expression, with preliminary studies showing potential for extending dosing intervals; the APGP6 project focuses on the differentiated therapeutic direction of fat reduction while preserving lean body mass during weight loss, providing new research reserves for the company's long-term layout in the metabolic disease field.
Comments